Aura Biosciences Inc AURA 深 沪
已收盘 04-02 16:00:00 美东时间
6.54
-0.160
-2.39%
华盛通- 最 高6.80
- 今 开6.55
- 成交量 17.58万股
- 最 低 6.53
- 昨 收 6.70
- 总市值 4.20亿
- 52周最高 7.4799
- 市盈率 静 --
- 换手率 0.27%
- 52周最低 4.345
- 委 比 -11.68%
- 总股本 6415.05万
- 历史最高 26.16
- 量 比 0.61
- 振 幅 4.03%
- 历史最低 4.345
- 每 手 1
- 风险率 0.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
Aura Biosciences Reports 2025 Results, Advances Bel-Sar Pipeline
An update from Aura Biosciences Inc ( ($AURA) ) is now available. On March 30, ...
03-30 20:10
Aura Biosciences presentation outlines bel-sar phase 3 program in early choroidal melanoma
Aura Biosciences presentation outlines bel-sar phase 3 program in early choroidal melanoma Aura Biosciences outlined plans to complete enrollment in phase 3 trial of belzupacap sarotalocan in early choroidal melanoma under an FDA special protocol assessment. Presentation highlighted phase 2 data sho
03-30 19:38
Aura Biosciences Q4 EPS $(0.37) Beats $(0.45) Estimate
Aura Biosciences (NASDAQ:AURA) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.78 percent. This is a 28.85 percent increase over losses of $(0.52) per share from
03-30 19:17
Aura Biosciences 2025 net loss widens as R&D costs rise
Aura Biosciences 2025 net loss widens as R&D costs rise Overview US biotech's 2025 net loss widened as R&D expenses rose for late-stage clinical trials General and administrative expenses declined, mainly due to reduced professional fees Company expects cash reserves to fund operations into Q1 2027
03-30 19:09
Aura Biosciences FY25 net loss widens 22.2% to $106M; R&D expense rises to $90M
Aura Biosciences FY25 net loss widens 22.2% to $106M; R&D expense rises to $90M Aura Biosciences posted a Q4 net loss of USD 26 million. Full-year net loss widened 22.2% to USD 110 million. Operating loss expanded to USD 110 million. R&D expense climbed to USD 90 million due to Phase 3 bel-sar trial
03-30 19:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Mon...
03-09 20:05
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.
03-09 16:54
Why High Roller Technologies Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Shares of High Roller Technologies Inc (NYSE:ROLR) rose sharply in pre-market t...
01-22 17:46
BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq 100 futures...
2025-12-19 21:08
